ArticleAnnals of internal medicine2019
Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management.
Article in Annals of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.JNCI cancer spectrum · 2024Trial
- Germline testing, access to genetic counseling, and treatment implications in advanced breast cancer.Annals of medicine and surgery (2012) · 2026Article
- Expanding access to cancer genetic care for cancer survivors: Rationale and design for a randomized controlled trial of a chatbot-based genetic education and testing.Contemporary clinical trials · 2026Article
- Putative breast cancer risk variants from populations of South Asian ancestry are under-represented in public variant classification databases.Breast cancer research : BCR · 2026Article
- Identifying CTSF and GSTM3 as chemoresistance therapeutic targets in breast cancer through multi-omics MR analysis.iScience · 2025Article
- Prognostic value of adjuvant chemotherapy for hormone receptor-negative T1a and T1bN0M0 breast cancer patients.Scientific reports · 2025Article
- Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study.Cancer research and treatment · 2024Article
- Article
- Prevalence of germline mutations in cancer susceptibility genes in Chinese patients with renal cell carcinoma.Translational andrology and urology · 2023Article
- Canine as a Comparative and Translational Model for Human Mammary Tumor.Journal of breast cancer · 2023Review
- Reduced Expression of KRT17 Predicts Poor Prognosis in HER2Biomolecules · 2022Article
- Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.Journal of personalized medicine · 2021Review
- Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes.Journal of personalized medicine · 2021Review
- Clinical implementation of an oncology-specific family health history risk assessment tool.Hereditary cancer in clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Personalization of care through precision medicine and, more specifically, genetic testing is altering the treatment of breast cancer. Genetic testing is used in germline and tumor testing, with each providing distinct data to guide management. Germline testing supports more accurate risk evaluation to inform screening and risk-reducing medical and surgical strategies. Tumor testing can inform cancer recurrence risk assessment and cancer treatment options. This article reviews how genetic testing informs treatment and potential risks for a patient with breast cancer and her family. Hereditary cancer genetic testing of family members should include a discussion of potential results, adverse effects, clinical management options, and insurance coverage and address concerns about privacy or discrimination. Genetic professionals are available to assist with educating, testing, and treating patients with increased cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.